Physician profile
Gary H Field
NPI 1366468209
$1,042.59
in general payments reported to CMS, 2019-2025
11 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $31.61 · 2021: $17.19 · 2022: $173 · 2024: $425 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.76 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.59 | 2019-2025 | Ozempic |
| Dexcom, INC. | $168.88 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $153.92 | 2025 | Twiist |
| Amgen INC. | $152.31 | 2022-2024 | Evenity |
| Lilly USA, LLC | $133.82 | 2022 | |
| Beta Bionics, INC. | $123.55 | 2024 | Ilet Bionic Pancreas |
| Neurocrine Biosciences, INC. | $24.04 | 2025 | |
| Tandem Diabetes Care, INC. | $18.11 | 2020 | |
| Acella Pharmaceuticals, LLC | $17.19 | 2021 | |
| Abbvie INC. | $14.68 | 2024 | |
| Medtronic Minimed, INC. | $13.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.